Here's what we'll cover
Here's what we'll cover
If you've been comparing GLP-1 medications, you may have noticed that Mounjaro and Zepbound keep coming up more and more. There's a concrete reason for that. Eli Lilly's tirzepatide-based drugs are pulling ahead of Novo Nordisk's semaglutide lineup in sales, and the gap is widening.
For patients and prospective patients, this isn't just a business story. It has practical implications for which medications your provider is likely to discuss, how supply chains are being managed, and potentially what you pay out of pocket.
What's Actually Driving the Sales Shift
Lilly's surge isn't happening in a vacuum. A few factors are converging to push Mounjaro and Zepbound ahead.
The Dual-Hormone Mechanism
Tirzepatide, the active ingredient in both Mounjaro and Zepbound, works on two receptors at once. It activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Semaglutide, the active ingredient in Ozempic and Wegovy, targets GLP-1 receptors only.
Clinical trial data from the SURMOUNT program showed that tirzepatide produced average weight loss of up to 22.5% of body weight in some participants over 72 weeks. This outpaced average results seen in semaglutide trials, which generally showed 15-17% weight loss.
These results have made tirzepatide increasingly attractive to both prescribers and patients looking for the most effective option available.
Supply Improvements
For much of 2023 and 2024, both Lilly and Novo Nordisk struggled to keep up with demand. Shortages affected patients across both drug families. Lilly has since scaled up manufacturing aggressively, which has helped improve availability of Mounjaro and Zepbound.
Improved supply means more patients can actually fill their prescriptions consistently, which contributes directly to sales growth and patient retention.
What This Means If You're Comparing Medications
The sales gap between tirzepatide and semaglutide matters to you as a patient primarily because of how it affects prescribing patterns and coverage decisions.
Providers Are Prescribing Tirzepatide More Often
When a medication demonstrates stronger clinical outcomes and becomes reliably available, providers naturally shift toward recommending it more frequently. If you're just starting a conversation with a doctor about GLP-1 therapy, there's a reasonable chance tirzepatide will come up early in the discussion.
That said, semaglutide remains a highly effective, well-studied medication. Ozempic has years of real-world data behind it for type 2 diabetes management, and Wegovy has a strong record in chronic weight management. The "best" drug depends on your specific health situation, not sales rankings.
Insurance Coverage Is Evolving
As tirzepatide gains market share, more insurance plans are updating their formularies to include it. This is important because coverage decisions affect your actual out-of-pocket cost more than any other factor.
Some plans that previously required semaglutide as a first-line therapy before covering tirzepatide are beginning to reconsider those step-therapy requirements. It's worth calling your insurer to ask specifically about current coverage for Mounjaro (if you have type 2 diabetes) or Zepbound (if your primary goal is weight loss).
Mounjaro vs. Zepbound: Same Drug, Different Approvals
A source of frequent confusion: Mounjaro and Zepbound contain the same active ingredient, tirzepatide. The difference is in their FDA-approved indications.
Which version your doctor prescribes, and which your insurance will cover, largely depends on your diagnosis. If you have type 2 diabetes, Mounjaro is likely the relevant option. If you're pursuing weight loss without a diabetes diagnosis, Zepbound is the indicated choice.
What Competition Between Lilly and Novo Nordisk Means for Pricing
When two companies are competing seriously for the same patients, pricing dynamics tend to shift in favor of consumers over time. This is already beginning to happen in the GLP-1 space.
Manufacturer Savings Programs
Both Lilly and Novo Nordisk have savings programs for eligible commercially insured patients. Lilly's savings card for Zepbound has allowed some patients to pay as little as $25 per month. These programs are a direct response to competition and patient advocacy around cost.
These offers change frequently and have eligibility restrictions, so check the current terms directly with the manufacturer or through a resource like GLP-1 Coupons before assuming you qualify.
Compounded Tirzepatide Is Changing
It's worth noting that the FDA's shortage designation for tirzepatide has been a moving target. When a drug is on the FDA shortage list, compounding pharmacies are permitted to produce copies of it. As Lilly's supply has improved, the FDA has taken steps to end the shortage designation for tirzepatide, which affects the availability of compounded versions.
If you've been using compounded tirzepatide, or were considering it as a lower-cost alternative, staying current on FDA shortage status is essential. The landscape has shifted and continues to evolve.
Dosing Timelines: What to Expect If You Start Tirzepatide
Whether you're prescribed Mounjaro or Zepbound, the dosing schedule follows the same structure. Starting doses are intentionally low to minimize side effects, with gradual increases over time.
Your provider may slow this titration schedule based on how you're tolerating the medication. Nausea, fatigue, and gastrointestinal discomfort are most common during dose increases and typically improve as your body adjusts.
Questions to Ask Your Doctor About This Market Shift
The fact that tirzepatide is outselling semaglutide doesn't automatically make it the right choice for you. Here are specific questions worth bringing to your next appointment:
- Based on my health profile, do you recommend tirzepatide or semaglutide, and why?
- Does my insurance currently cover Zepbound or Mounjaro, or would Wegovy or Ozempic be easier to get covered?
- Has your practice seen better outcomes with tirzepatide compared to semaglutide in patients similar to me?
- If I start one medication and it's not working well, how do we evaluate switching?
- Are there reasons I shouldn't use a dual-agonist medication like tirzepatide?
These questions shift the conversation from following market trends to making a decision that's grounded in your specific situation.
How to Find a Provider Who Offers Tirzepatide
Access to tirzepatide depends heavily on finding a provider who is both comfortable prescribing it and able to help you navigate insurance coverage. Telehealth platforms have dramatically expanded access to GLP-1 prescriptions, including tirzepatide, without requiring in-person visits for eligible patients.
When comparing providers, look for platforms that offer insurance verification support, transparent pricing for self-pay patients, and ongoing monitoring rather than just a one-time prescription. You can compare options through Best Providers to see which platforms currently offer tirzepatide and what their costs look like.
No waiting list. No insurance needed.
Frequently Asked Questions
Is Mounjaro better than Ozempic for weight loss?
Clinical trials suggest tirzepatide (Mounjaro/Zepbound) produces greater average weight loss than semaglutide (Ozempic/Wegovy), with some participants losing up to 22.5% of body weight. However, individual results vary, and your doctor should help you choose based on your health history, not trial averages alone.
What is the difference between Mounjaro and Zepbound?
Both contain tirzepatide, the same active drug. Mounjaro is FDA-approved specifically for type 2 diabetes management, while Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition. Your diagnosis typically determines which version is prescribed and which your insurance will cover.
Why are Mounjaro and Zepbound sales surging?
Several factors are driving growth: strong clinical trial results showing substantial weight loss, improved manufacturing that has eased supply shortages, growing prescriber familiarity, and expanding insurance coverage. Patients and providers are increasingly choosing tirzepatide based on both efficacy data and improved access.
Can I get Zepbound for $25 a month?
Eli Lilly has offered a savings card that can reduce costs to as low as $25 per month for eligible commercially insured patients. This offer has eligibility restrictions and may change, so verify current terms through Lilly's website or through a GLP-1 coupon resource before assuming you qualify.
Is compounded tirzepatide still available?
Compounded tirzepatide was widely available when the FDA listed tirzepatide as being in shortage. As Lilly's supply has improved, the FDA has moved to remove tirzepatide from the shortage list, which limits when compounders can legally produce copies. Check the FDA's current shortage database for the latest status.
How long does it take for Mounjaro or Zepbound to work?
Most patients begin to notice appetite suppression within the first few weeks. Meaningful weight loss typically becomes apparent after 8-12 weeks, with more significant results building over 6-12 months of consistent use at an effective dose. Full titration to the maintenance dose takes several months.
The Bottom Line: Sales Numbers Are Context, Not a Prescription
The fact that Mounjaro and Zepbound are outpacing Novo Nordisk's medications is a meaningful signal about where the GLP-1 market is heading. It reflects real clinical data, improving supply, and growing confidence among prescribers. Those are all relevant data points when you're deciding what to ask about.
But a medication's market share doesn't replace a personalized clinical assessment. Semaglutide continues to help millions of patients effectively manage weight and blood sugar. Some patients do better on it than on tirzepatide. Tolerability, insurance coverage, your specific health conditions, and what your provider has experience managing all matter just as much as which drug is currently at the top of the sales charts.
What This Moment Means Practically
If you're already on semaglutide and doing well, there's no reason to switch just because tirzepatide is trending. If you're just starting out, or haven't seen the results you hoped for, this is a good time to have a direct conversation with your doctor about whether tirzepatide makes sense as your starting point or next step.
The broader competition between Lilly and Novo Nordisk is also likely to benefit patients over time through better pricing incentives, expanded insurance coverage, and continued investment in next-generation treatments.
Start With the Right Information
Before your next provider conversation, take a few minutes to understand your current options. GLP-1.com keeps track of the latest pricing, provider comparisons, and coverage information so you don't have to piece it together from scattered sources.
You can explore current GLP-1 Coupons for both tirzepatide and semaglutide medications, compare telehealth and in-person providers offering GLP-1 prescriptions, and review detailed medication guides for Mounjaro, Wegovy, and Ozempic.
Always consult your physician or a qualified healthcare provider before starting, switching, or stopping any GLP-1 medication. The right choice is one that fits your full health picture, not just what's selling most.